...
首页> 外文期刊>Disease markers >Plasma Inter-Alpha-Trypsin Inhibitor Heavy Chains H3 and H4 Serve as Novel Diagnostic Biomarkers in Human Colorectal Cancer
【24h】

Plasma Inter-Alpha-Trypsin Inhibitor Heavy Chains H3 and H4 Serve as Novel Diagnostic Biomarkers in Human Colorectal Cancer

机译:血浆间α-胰蛋白酶抑制剂H3和H4作为人结肠直肠癌的新型诊断生物标志物

获取原文
           

摘要

Objective. Inter-alpha-trypsin inhibitor heavy chain H3 (ITIH3) and inter-alpha-trypsin inhibitor heavy chain H4 (ITIH4) are heavy chains of protein members belonging to the ITI family, which was associated with inflammation and carcinogenesis. However, the diagnostic value of ITIH3 and ITIH4 in human colorectal cancer (CRC) remains unknown. Methods. In total, 101 CRC patients and 156 healthy controls were enrolled. The concentrations of ITIH3 and ITIH4 proteins in plasma samples of participants were assessed using enzyme-linked immunosorbent assay. ITIH3 and ITIH4 expressions in human CRC tissues were additionally assessed via immunohistochemical staining (IHC). Receiver operating characteristic (ROC) was applied to estimate the diagnostic power of the two proteins, and the net reclassification improvement (NRI) was adopted to evaluate the incremental predictive ability of ITIH3/ITIH4 when added to the tissue inhibitor of metalloproteinase-1 (TIMP-1). Results. The plasma concentration of ITIH3 in CRC patients (median: 4.370 μg/mL; range: 2.152–8.170?μg/mL) was significantly lower than that in healthy subjects (median: 4.715 μg/mL; range: 2.665–10.257?μg/mL; p0.001), while the ITIH4 plasma level in subjects with CRC (median: 0.211 μg/mL; range: 0.099–0.592?μg/mL) was markedly increased relative to that in the control group (median: 0.134 μg/mL; range: 0.094–0.460?μg/mL, p0.001). Consistently, IHC score assessment showed a dramatic reduction in ITIH3 expression and, conversely, upregulation of ITIH4 in colorectal carcinoma specimens relative to adjacent normal colorectal tissues (p0.001 in both cases). The area under the curve (AUC) of the ROC for ITIH4 (AUC=0.801, 95% CI: 0.745–0.857) was higher than that for ITIH3 (AUC=0.638, 95% CI: 0.571–0.704, both p values 0.001). The AUC of the ROC for combined ITIH3 and ITIH4 was even higher than that for carcinoembryonic antigen. NRI results showed that combining ITIH3 and ITIH4 with TIMP-1 significantly improved diagnostic accuracy (NRI=17.12%, p=0.002) for CRC patients compared to TIMP-1 alone. Conclusions. Circulating ITIH3 and ITIH4 levels are associated with carcinogenesis in CRC, supporting their potential diagnostic utility as surrogate biomarkers for colorectal cancer detection.
机译:客观的。 α-胰蛋白酶抑制剂重链H3(ITIH3)和α-胰蛋白酶间抑制剂重链H4(ITIH4)是属于ITI家族的蛋白质成员的重链,其与炎症和致癌作用有关。然而,ITIH3和ITIH4在人结肠直肠癌(CRC)中的诊断值仍然未知。方法。总共有101例CRC患者和156例健康对照。使用酶联免疫吸附测定评估参与者的血浆样品中ITIH3和ITIH4蛋白的浓度。通过免疫组织化学染色(IHC)评估人CRC组织中的ITIH3和ITIH4表达。应用接收器操作特征(ROC)估计两种蛋白质的诊断功能,采用净重新分类改善(NRI)评估ITIH3 / ITIH4加入金属蛋白酶-1的组织抑制剂时的增量预测能力(TIMP -1)。结果。 ITIH3在CRC患者中的血浆浓度(中位数:4.370μg/ ml;范围:2.152-8.170?μg/ ml)显着低于健康受试者(中位数:4.715μg/ ml;范围:2.665-10.257?μg/ ML; P <0.001),而ITIH4在CRC的受试者中的ITIH4血浆水平(中值:0.211μg/ ml;范围:0.099-0.592≤μg/ mL)相对于对照组显着增加(中位数:0.134μg/ ml;范围:0.094-0.460?μg/ ml,p <0.001)。始终如一地,IHC评分评估表明ITIH3表达的显着降低,相反,相对于相同的正常结直肠组织的结肠直肠癌标本中的ITIH4的上调(两种情况下P <0.001)。 IH4(AUC = 0.801,95%CI:0.745-0.857)的ROC曲线(AUC)下的区域高于ITIH3(AUC = 0.638,95%CI:0.571-0.704,P值<0.001 )。合并ITIH3和ITIH4的ROC的AUC甚至高于癌胚抗原的均匀。 NRI结果表明,与单独的TIMP-1相比,CRC患者的诊断精度(NRI = 17.12%,P = 0.002)与TIMP-1相结合,与TIMP-1相结合。结论。循环ITIH3和ITIH4水平与CRC中的致癌有关,支持其潜在的诊断用途作为结肠直肠癌检测的替代生物标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号